Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis

Leptomeningeal disease (LMD) is a common complication from solid tumor malignancies with a poor prognosis and limited treatment options. We present a single arm Phase II study of 18 patients with LMD receiving combined ipilimumab and nivolumab until progression or unacceptable toxicity (NCT02939300)...

Descripción completa

Detalles Bibliográficos
Autores principales: Brastianos, Priscilla K., Strickland, Matthew R., Lee, Eudocia Quant, Wang, Nancy, Cohen, Justine V., Chukwueke, Ugonma, Forst, Deborah Anne, Eichler, April, Overmoyer, Beth, Lin, Nancy U., Chen, Wendy Y., Bardia, Aditya, Juric, Dejan, Dagogo-Jack, Ibiayi, White, Michael D., Dietrich, Jorg, Nayyar, Naema, Kim, Albert E., Alvarez-Breckenridge, Christopher, Mahar, Maura, Mora, Joana L., Nahed, Brian V., Jones, Pamela S., Shih, Helen A., Gerstner, Elizabeth R., Giobbie-Hurder, Anita, Carter, Scott L., Oh, Kevin, Cahill, Daniel P., Sullivan, Ryan J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8511104/
https://www.ncbi.nlm.nih.gov/pubmed/34642329
http://dx.doi.org/10.1038/s41467-021-25859-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8511104/
https://www.ncbi.nlm.nih.gov/pubmed/34642329
http://dx.doi.org/10.1038/s41467-021-25859-y

Ejemplares similares